

1 **Assessment of the infectious threshold of SARS-CoV-2 in primary airway epithelial cells**

2 **Running Title:** SARS-CoV2 isolation in HAE and Vero E6

3 Manel Essaidi-Laziosi<sup>1</sup>, Francisco Javier Perez Rodriguez<sup>2</sup>, Pascale Sattonnet-Roche<sup>2</sup>, Nicolas

4 Hulo<sup>3</sup>, Frederique Jacquieroz<sup>2</sup>, Laurent Kaiser<sup>2</sup> and Isabella Eckerle<sup>1,2</sup>

5

6 <sup>1</sup>Department of Microbiology and Molecular Medicine, University of Geneva, Geneva,

7 Switzerland

8 <sup>2</sup>Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.

9 <sup>3</sup>Service for Biomathematical and Biostatistical Analyses. Institute of Genetics and Genomics,

10 University of Geneva, Geneva, Switzerland

11

12 *Corresponding author:* Isabella Eckerle, Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals,

13 Geneva, Switzerland. Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland. Tel:

14 +41223729820; FAX: +41223724097; Email: [isabella.eckerle@unige.ch](mailto:isabella.eckerle@unige.ch)

15 Alternate corresponding author. Manel Essaidi-Laziosi, Department of Microbiology and Molecular Medicine,

16 Faculty of Medicine of Geneva, University of Geneva, Geneva, Switzerland. Rue Michel-Servet 1, 1205 Geneva.

17 Tel. +41223795528, Email: [Manel.Essaidi@unige.ch](mailto:Manel.Essaidi@unige.ch)

18

19 **Key words**

20 SARS-CoV-2

21 COVID-19

22 Airway epithelium

23 Virus isolation

24 Infectiousness

25 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 Comparison of virus isolation success from clinical samples across a range of viral loads  
28 inoculated in parallel on Vero E6 and human airway epithelia (HAE) showed lower success of  
29 virus isolation in HAE, suggesting an overestimation of actual infectiousness in humans using  
30 Vero E6 cell lines, commonly considered as reference.

31

32 **Main text**

33 Understanding the window of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-  
34 2) infectiousness is essential for the control of the coronavirus disease 19 (COVID-19)  
35 pandemic. Thanks to its high sensitivity and rapidity, real time RT-PCR remains the gold  
36 standard for diagnosing SARS-CoV-2. However, detection of viral RNA by this method does not  
37 necessarily equate with the presence of infectious viral particles, the requisite for  
38 transmission.

39 Although resource-intensive (as dependent on biosafety level-3 facilities) and not suitable for  
40 routine diagnostic purposes, inoculation of patient's specimens on cultured cells is to date the  
41 only method to confirm presence of infectious SARS-CoV-2 in a sample. A number of studies  
42 highlighted two determinants of the presence of infectious particles: SARS-CoV-2 RNA copy  
43 numbers (RNA<sub>c</sub>) per mL in the original specimens, as determined by RT-PCR, and the symptom  
44 duration. The probability of isolating viable virus hence appears to be drastically reduced  
45 below 5.4-7 log<sub>10</sub> RNA<sub>c</sub>/mL, and after more than one week of symptoms [1-3].

46 The vast majority of these investigations used Vero E6 cells, derived from the kidney of an  
47 African Green Monkey, although several other conventional Human cell lines, such as Caco2  
48 (colorectal adenocarcinoma) and Calu3 (lung cancer cells) were also found to be susceptible  
49 [4]. As they are interferon-production deficient [5] and express the virus receptor [6], Vero E6  
50 cells are highly susceptible to SARS-CoV-2 and thus are the most widely used reference cell  
51 line for isolation. However, these cells do not mimic the *in vivo* situation of the SARS-CoV-2  
52 entry site, which is the human respiratory tract. The use of reconstituted human primary  
53 airway epithelial cells (HAE) better reflects SARS-CoV-2 infection characteristics *in vivo*.

54 To assess of the threshold for the presence of infectious virus in this more relevant model  
55 system, we compared virus isolation success from clinical samples across a range of viral loads

56 (VLs) inoculated in parallel on Vero E6 and HAE. We found that this threshold is higher in HAE  
57 compared to Vero E6, suggesting the presence of infectious virus as determined by Vero E6  
58 would not necessarily be sufficient to lead to an infection in HAE.

59 In this study, we used nasopharyngeal swabs collected in viral transport medium from  
60 symptomatic adult individuals presenting at the outpatient testing center of the University  
61 Hospitals of Geneva, spanning the first pandemic wave in spring 2020 and a second pandemic  
62 wave in fall 2020, that tested positive for SARS-CoV-2 by RT-PCR (Cobas® SARS-CoV-2 Test,  
63 Cobas 6800, Roche, Switzerland). All samples were collected from patients within the first 5  
64 days post onset of symptoms (dpos), diagnosed between April and September 2020. All  
65 viruses circulating during the investigated time period were characterized by the D614G  
66 mutation, but no variants of concern were circulating in Switzerland during that time. VLs were  
67 calculated for the E gene target as previously described [7]. In order to avoid loss of infectivity,  
68 all samples were frozen at -80°C after diagnostic testing. Their inoculation was performed  
69 immediately after a single thawing (there were no repeated freeze-thaw cycles). Regarding  
70 virus isolation, 100 µl of the original clinical sample was inoculated in parallel on Vero E6 cells  
71 grown in 48 well plates and in HAE (MucilAir™ commercially available, Epithelix SARL), with  
72 an approximate number of cells for both culture systems of 2E+05 cells per well. Infections  
73 were performed at 37°C under a 5% CO<sub>2</sub> atmosphere as previously described [8, 9]. Viral  
74 replication was assessed by quantitative RT-PCR from RNA extracted from the supernatant  
75 collected at 1 hour post infection (hpi) for Vero E6 and from apical tissue washes 3hpi for HAE,  
76 and at the end of the experiment 6 days post infection (dpi). Successful virus isolation was  
77 determined by at least 3log<sub>10</sub> folds increase of RNAc between baseline and 6 dpi.

78 In total, 38 primary clinical specimens were inoculated in parallel, with a VL ranging from 5.7-  
79 9.0 log<sub>10</sub> SARS-CoV-2 RNAc/mL in the original sample. The overall frequency of successful virus

80 isolation was 27/38 in Vero E6 and 12/38 in HAE (Figure 1A and Table S1). No growth in either  
81 cell culture system was observed in samples below 5.8 log<sub>10</sub> RNAc/mL. The lowest VL from  
82 which infectious virus could be isolated in Vero E6 was 5.9 log<sub>10</sub> RNAc/mL and 6.3 log<sub>10</sub>  
83 RNAc/mL for HAE (Figures 1A). Although two samples with rather low viral load of 6.3 and 6.5  
84 log<sub>10</sub> RNAc/mL showed successful isolation in HAE, consistent isolation of virus was only  
85 observed in samples with a VL of 7.7 log<sub>10</sub> RNAc/mL and higher. Using Probit analysis, the  
86 probability of a sample being infectious in Vero E6 and HAE was below 5% when VL was lower  
87 than 5.5 and 6.5 log<sub>10</sub> SARS-CoV-2 RNAc/mL, respectively (p value <0.05). No correlation was  
88 found between the number of dpos within the first 5 dpos and successful viral growth in both  
89 models (in order to increase the likelihood of infectious virus presence, only samples from  
90 patients ≤ 5 dpos were selected) (Table S1).

91 Upon successful isolation, the virus showed replication to higher viral loads in Vero E6 (mean  
92 VL of 12.1 log<sub>10</sub> SARS-CoV-2 RNAc/mL, SD ± 0.7, range 11.1-14.06) compared to HAE (mean VL  
93 of 10.3 log<sub>10</sub> SARS-CoV-2 RNAc/mL, SD ± 1.4 range 6.1-11.4) at the end of the experiment (6  
94 dpi, Figure 1B). In conclusion, upon comparative virus isolation, we could recapitulate findings  
95 from earlier studies on Vero E6 with successful virus isolation in a similar range as previously  
96 reported. In the HAE model, however, virus isolation was only consistently successful in  
97 samples with a VLs of ≥7.7 RNAc/mL (Figure 1A), but there were two outliers of successful  
98 isolation with a much lower VL. In conclusion, Vero E6 cells are shown to be more permissive  
99 for SARS-CoV-2 isolation and yield virus isolates from samples with lower VLs than HAE.  
100 Furthermore, upon successful isolation, SARS-CoV-2 replicates in Vero E6 to higher virus titers  
101 than in HAE.

102 Lower success of virus isolation in HAE, and thus a higher amount of infectious virus particles  
103 needed to start an infection, could hint towards an overestimation of actual infectiousness in

104 humans when only using Vero E6 cell lines as a reference. This could mean that the actual  
105 transmission risk would be lower than findings based on Vero E6 culture data and that  
106 transmission-relevant infectious virus shedding is shorter and/or lower than what was  
107 previously estimated. Furthermore, antigen-based rapid diagnostic tests, which have a lower  
108 sensitivity than PCR but may detect infections with VLs as low as  $6 \log_{10}$  RNAc/mL [10], would  
109 thus be an even better at identifying infectious individuals than previously believed. Further  
110 research is still needed to investigate the infectious doses of SARS-CoV-2 under real life  
111 conditions. Even if the presence of such infectious virus is not enough to predict the  
112 transmission risk, as multiple factors influence transmission, VL constitutes one of the most  
113 important drivers of transmission [11].

114 As the infectious dose of SARS-CoV-2 still needs to be determined *in vivo* [12], and HAEs do  
115 not completely recapitulate the *in vivo* situation, our study cannot be used to change existing  
116 guidelines on isolation or discharge criteria. It nevertheless emphasizes the effect of the cell  
117 lines used to culture the virus and thus supports the use of models that more closely reflect  
118 the *in vivo* situation, such as HAE in air-liquid interface culture rather than conventional cell  
119 lines, in order to better understand transmission risks of SARS-CoV-2 in patients.

## 120 **Acknowledgments**

121 We thank Catia Alvarez for excellent technical support and Erik Boehm for English proof  
122 reading (Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,  
123 Switzerland).

## 124 **Funding**

125 This work was supported by the Private HUG Foundation, by the Pictet Charitable Foundation  
126 and by the Swiss National Science Foundation (grant Nr. 196644, 196383).


127

128 **References**

- 129 1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized  
130 patients with COVID-2019. *Nature* **2020**; 581(7809): 465-9.
- 131 2. Bullard J, Dust K, Funk D, et al. May 2020. Predicting infectious SARS-CoV-2 from  
132 diagnostic samples. *Clin Infect Dis* doi 10.
- 133 3. van Kampen JJ, van de Vijver DA, Fraaij PL, et al. Duration and key determinants of  
134 infectious virus shedding in hospitalized patients with coronavirus disease-2019  
135 (COVID-19). *Nature communications* **2021**; 12(1): 1-6.
- 136 4. Chu H, Chan JF-W, Yuen TT-T, et al. Comparative tropism, replication kinetics, and cell  
137 damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical  
138 manifestations, transmissibility, and laboratory studies of COVID-19: an observational  
139 study. *The Lancet Microbe* **2020**; 1(1): e14-e23.
- 140 5. Chew T, Noyce R, Collins SE, Hancock MH, Mossman KL. Characterization of the  
141 interferon regulatory factor 3-mediated antiviral response in a cell line deficient for  
142 IFN production. *Molecular immunology* **2009**; 46(3): 393-9.
- 143 6. Ren X, Glende J, Al-Falah M, et al. Analysis of ACE2 in polarized epithelial cells: surface  
144 expression and function as receptor for severe acute respiratory syndrome-associated  
145 coronavirus. *Journal of general virology* **2006**; 87(6): 1691-5.
- 146 7. Baggio S, L'Huillier AG, Yerly S, et al. Severe Acute Respiratory Syndrome Coronavirus  
147 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With  
148 Early Acute Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases* **2020**.
- 149 8. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-competent SARS-CoV-2 in  
150 nasopharynx of symptomatic neonates, children, and adolescents. *Emerging infectious  
151 diseases* **2020**; 26(10): 2494.
- 152 9. Essaidi-Laziosi M, Brito F, Benaoudia S, et al. Propagation of respiratory viruses in  
153 human airway epithelia reveals persistent virus-specific signatures. *Journal of Allergy  
154 and Clinical Immunology* **2018**; 141(6): 2074-84.
- 155 10. Berger A, Nsoga MTN, Perez-Rodriguez FJ, et al. Diagnostic accuracy of two commercial  
156 SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based  
157 testing centers. *Plos one* **2021**; 16(3): e0248921.
- 158 11. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters  
159 in Catalonia, Spain: a cohort study. *The Lancet Infectious Diseases* **2021**.
- 160 12. Karimzadeh S, Bhopal R, Tien HN. Review of infective dose, routes of transmission, and  
161 outcome of COVID-19 caused by the SARS-CoV-2 Virus: comparison with other  
162 respiratory viruses. **2020**.

164

165




166  
167 Figure 1. Comparative virus isolation in Vero E6 versus reconstituted human primary airway  
168 epithelial cells (HAE). **A** Comparative virus isolation success in Vero E6 versus HAE.  
169 Comparing baseline to 6 dpi, the success of isolation was determined and presented as  
170 follow: ○: unsuccessful isolation; ◐ : successful isolation only in Vero E6; ● : successful  
171 isolation Vero E6 and HAE. **B**. SARS-CoV-2 viral loads 6 dpi after successful isolation in cell  
172 culture supernatant (Vero E6) and apical washes (HAE). Statistical significance was calculated  
173 using t test (\*\*\*\*: p< 0.0001).

174  
175

Sample ID	SARS-CoV-2 log10 RNA copies/mL	Days post symptoms	SARS-CoV-2 isolation	
			Vero E6	HAE
1	5.7	3	-	-
2	5.7	4	-	-
3	5.8	4	-	-
4	5.8	1	-	-
5	5.8	5	-	-
6	5.8	1	-	-
7	5.9	4	-	-
8	5.9	3	+	-
9	6.0	0	-	-
10	6.0	3	+	-
11	6.0	5	-	-
12	6.3	2	+	+
13	6.3	2	+	-
14	6.5	1	+	+
15	6.5	1	-	-
16	6.5	0	-	-
17	6.6	2	+	-
18	6.6	1	+	-
19	6.7	4	+	-
20	6.7	4	+	-
21	6.7	1	+	-
22	6.8	2	+	-
23	6.8	1	+	-
24	6.8	3	+	-
25	6.9	3	+	-
26	7.0	4	+	-
27	7.0	0	+	-
28	7.0	4	+	-
29	7.7	3	+	+
30	7.7	4	+	+
31	7.9	5	+	+
32	8.0	1	+	+
33	8.0	0	+	+
34	8.0	3	+	+
35	8.7	4	+	+
36	8.8	3	+	+
37	8.8	3	+	+
38	9.0	1	+	+

176 Table S1. Sample characteristics

177

**A****B**